Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
8.05
-0.01 (-0.12%)
At close: Aug 28, 2025, 4:00 PM
8.05
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:10 PM EDT
Company Description
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd.
| Country | Israel |
| Founded | 1 |
| IPO Date | Aug 14, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Dan Teleman |
Contact Details
Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel | |
| Phone | 972 3 573 6632 |
| Website | nasuspharma.com |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0002029039 |
| Employer ID | 51-6022712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Udi Gilboa | Co-Founder and Executive Chairman of the Board of Directors |
| Dr. Dalia Megiddo | Co-Founder, Director, Chief Development Officer and Chief Medical Officer |
| Tair Lapidot, Pd.D. | Vice President of Research and Development and Clinical Development |
| Galia Temtsin Kryaz, Ph.D. | Director of CMC and Product Development |
| Oren Elmaliach | Director of Finance |
| Dr. Ronnie Hershman | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | 6-K | Report of foreign issuer |
| Aug 14, 2025 | 424B4 | Prospectus |
| Aug 12, 2025 | EFFECT | Notice of Effectiveness |
| Aug 12, 2025 | CERT | Certification by an exchange approving securities for listing |
| Aug 8, 2025 | 8-A12B | Registration of securities |
| Aug 7, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 30, 2025 | FWP | Free Writing Prospectus |
| Jul 28, 2025 | FWP | Free Writing Prospectus |
| Jul 28, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |